Announcements Trials
Browse Landscape

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Observational 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 13Urinary Bladder Neoplasms 1Neoplasms, Unknown Primary 1Neoplasms 1Neoplasm Metastasis 1Lung Neoplasms 1Glioblastoma 1Genomic Instability 1Carcinoma, Hepatocellular 1Biliary Tract Neoplasms 1Advanced Unresectable or Metastatic Solid Malignancy 1Adenocarcinoma of Lung 1ALK-positive NSCLC 1ALK+ Advanced NSCLC 1ALK Gene Rearrangement Positive 1

Interventions

lorlatinib 1ceritinib 1brigatinib 1alectinib 1Crizotinib 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Completed × ALK-positive NSCLC × alectinib × Clear all
NCT04647110 2023-04-06

Real-world Therapy of ALK-positive NSCLC in Sweden: the Sequencing of ALK Tyrosine Kinase Inhibitor Drugs and Their Therapeutic Outcomes Based on Data From National Registers.

Pfizer

Completed
549 enrolled 28 charts
Thoracic

ALK-positive NSCLC

Data powered by HemOnc (CC BY 4.0) Colophon âš¡